Reports Q1 revenue $293,000 vs. $1.93M last year. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx (MGTX) – we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years,” said Alexandria Forbes, president and chief executive officer of MeiraGTx. “The compelling three-year durability data from our AAV2-hAQP1 Phase 1 study continue to demonstrate disease-modifying benefit following a simple one-time treatment of patients with moderate to severe persistent radiation-induced xerostomia, an otherwise debilitating life-long condition. The recent receipt of Breakthrough Therapy Designation for this program reinforces the strength of the data and the potential for an expedited development and regulatory pathway.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- FDA Commissioner Marty Makary resigns
- Trump Trade: Trump to suspend tariff-rate quotas on beef imports
- Trump Trade: U.S. plans AI security order without required model tests
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- MeiraGTx Forms Strategic Gene Therapy Collaboration with Hologen